Yes, a patient with a GFR of 29 mL/min/1.73 m² can safely take Zetia (ezetimibe).
Ezetimibe is explicitly safe and recommended for patients with advanced chronic kidney disease, including those with a GFR of 29 mL/min/1.73 m² 1, 2. In fact, this patient falls into the exact population where ezetimibe use is strongly supported by guideline evidence.
Why Ezetimibe is Safe at This GFR Level
Pharmacokinetic Safety Profile
The FDA drug label specifically addresses severe renal impairment and demonstrates that ezetimibe exposure increases only approximately 1.5-fold in patients with severe renal disease (CrCl ≤30 mL/min/1.73 m²) 3. This modest increase is clinically insignificant and does not require dose adjustment. Unlike many medications that accumulate dangerously in kidney disease, ezetimibe is primarily eliminated through fecal excretion (78% of the dose), with only 11% excreted renally 3, 4.
Strong Guideline Support
The 2014 KDIGO Clinical Practice Guideline provides a Grade 1A recommendation (the highest level of evidence) for treating patients aged ≥50 years with eGFR <60 mL/min/1.73 m² using either a statin alone or a statin/ezetimibe combination 1, 2. Your patient with a GFR of 29 falls into CKD stage G4, which is specifically included in this recommendation (categories G3a–G5).
Clinical Evidence Supporting Use
The landmark SHARP trial demonstrated that simvastatin/ezetimibe combination therapy significantly reduces major atherosclerotic events in patients with GFR categories G3a–G5 1. This evidence is particularly relevant because:
- Patients with CKD stage 4 (GFR 15-29) have markedly elevated cardiovascular risk that exceeds 10 events per 1000 patient-years
- The absolute benefit of lipid-lowering therapy is actually greater in advanced CKD due to higher baseline cardiovascular risk
- Recent research confirms ezetimibe can be safely administered to CKD patients and may provide renal protection 5, 6
Practical Considerations
Dosing
- Standard dose of 10 mg daily requires no adjustment for renal impairment 3
- Can be taken morning or evening, with or without food
- No need for routine monitoring of drug levels
Safety Monitoring
A 2025 study specifically examined ezetimibe in patients with CKD and found:
- Mean LDL reduction of 27.0% in CKD patients (actually greater than in non-CKD patients) 6
- Muscle-related adverse events occurred in 13.9% of patients, with no difference between CKD and non-CKD groups
- Despite increased drug accumulation in CKD, this did not correlate with increased adverse events 6
Important Caveats
- Avoid if moderate-to-severe hepatic impairment is present (ezetimibe is not recommended in Child-Pugh score ≥7) 3
- If the patient is on cyclosporine, monitor carefully as ezetimibe exposure increases 2.4-fold 3
- Do not use ezetimibe monotherapy as primary therapy; it should be combined with a statin unless the patient is statin-intolerant 7
- If using cholestyramine, separate administration by several hours as it reduces ezetimibe absorption by 55% 3
When to Use Ezetimibe in This Patient
If age ≥50 years: Strongly recommended as part of statin/ezetimibe combination therapy regardless of LDL level 1, 2
If age 18-49 years: Recommended if the patient has any of the following:
- Known coronary disease
- Diabetes mellitus
- Prior ischemic stroke
- Estimated 10-year cardiovascular risk ≥10% 1
If already on dialysis: Continue ezetimibe if the patient was taking it before dialysis initiation, especially if ASCVD is present, but do not newly initiate 7
The evidence overwhelmingly supports that ezetimibe is both safe and beneficial for your patient with GFR 29, with no dose adjustment needed and a favorable risk-benefit profile that actually improves with advancing CKD due to higher baseline cardiovascular risk.